Please login to the form below

Not currently logged in
Email:
Password:

NICE Innovation report published

An independent study into how NICE establishes the value of innovation has been published

An independent study into how the National Institute for Health and Clinical Excellence (NICE) establishes the value of innovation has been published, and was presented by Sir Ian Kennedy at the public NICE Board meeting on July 22.

The report, carried out by Sir Ian Kennedy, provides several recommendations including how NICE can ensure its approach to establishing the value of new health technologies takes innovation into account and how innovation in health technologies should be defined. It report was commissioned in response to the views expressed by Sir David Cooksey in his Review and Refresh of Bioscience 2015. As part of the study interested parties - including the ABPI, NICE, a number of pharmaceutical companies and several patient groups - provided submissions.

This was followed up with a number of workshops exploring key issues with representatives from the NHS, healthcare professionals, healthcare industries, patients and the wider public. NICE's Citizen's Council also contributed its views to the study.

NICE chairman, professor Sir Michael Rawlins said: "We are very grateful to Sir Ian for his report on the value of innovation, and for broad confidence he has expressed in NICE and its methods. Since NICE was established we have regularly consulted on our approach to valuing the benefits of new technologies and we welcome the opportunity to focus on innovation. Sir Ian's report raises a number of issues that NICE will need to consider. NICE's Board will set out a formal response at its next public Board meeting in September, which will then be the subject of a three-month consultation."

22nd July 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics